A large analysis of electronic health records from a Texas medical center has found that GLP-1 class drugs, along with a related class of diabetes medications, were associated with lower cancer rates among diabetes patients — though researchers caution the study cannot prove the drugs caused the reduction.
The analysis drew on records from 359,595 adults treated at the center between January 2010 and July 2025, comparing cancer rates among patients prescribed different diabetes medications. Among patients with the most advanced diabetes, particularly those with significant heart or kidney complications, SGLT2 inhibitors — a different class of diabetes drug often prescribed alongside or instead of GLP-1 medications — were associated with the lowest cancer rates of any group studied. The association between GLP-1 drugs specifically and lower cancer rates was not consistent across all five comparisons the researchers ran.
The findings add to a growing, if still unsettled, body of research examining whether the class of drugs that includes semaglutide and similar medications — originally developed for diabetes and now widely used for weight loss — may carry knock-on effects for cancer risk. A separate study from UC San Diego, examining more than 6,800 colon cancer patients, found GLP-1 medications associated with longer survival, which researchers there attributed to the drugs' effects on inflammation and metabolic health.
Because both studies are observational — drawing associations from medical records rather than randomized trials — researchers caution against drawing firm conclusions about cause and effect. Patients prescribed one class of drug over another may differ in other ways that affect cancer risk, a limitation inherent to this kind of retrospective analysis. Still, the scale of the Texas dataset gives the findings more statistical weight than smaller studies, and researchers say the results justify further investigation through more rigorous trial designs.